Theranostical nanosystem‐mediated identification of an oncogene and highly effective therapy in hepatocellular carcinoma

• DOI: 10.1002/hep.28409
• Publication Date: 2015-12-17T15:22:50Z
• Authors: Yu Guo; Jing Wang; Lu Zhang; Shunli Shen; Ruomi Guo; Yang Yang; Wenjie Chen; Yiru Wang; Guihua Chen; Xintao Shuai
• Keywords: Male; Analysis of Variance; 0303 health sciences; Carcinoma, Hepatocellular; Liver Neoplasms; Mice, Nude; Apoptosis; Genetic Therapy; Kaplan-Meier Estimate; Middle Aged; Magnetic Resonance Imaging; 3. Good health; Gene Expression Regulation, Neoplastic; Disease Models, Animal; Mice; 03 medical and health sciences; Multivariate Analysis; Animals; Heterografts; Humans; Female; Molecular Targeted Therapy; Aged

Because the primary surgical treatment options for hepatocellular carcinoma (HCC)—including hepatic resection and liver transplantation—often fail due to recurrence metastasis, identifying early prognostic biomarkers therapeutic targets HCC is of great importance. This study shows that transducin β‐like protein 1–related (TBLR1) a key oncogene plays important roles in proliferation, antiapoptosis, angiogenesis by regulating Wnt/β‐catenin pathway. The folate‐targeted theranostic small interfering RNA (siRNA) nanomedicine Fa‐PEG ‐g‐ PEI‐SPION/ p siRNA‐TBLR1 effectively silences TBLR1 gene different human cell lines vitro samples vivo , resulting simultaneous suppression angiogenesis. its multi‐anticancer functions against HCC, intravenous injection siRNA into nude mice bearing intrahepatic or subcutaneous xenografts has significant effect. Tumor growth those animals was almost completely inhibited with siRNA‐TBLR1. Moreover, SPION‐encapsulated polyplexes possess high magnetic resonance imaging (MRI) detection sensitivity, which makes tumor‐targeted delivery easily trackable using clinical MRI technique. Conclusion : examined here possesses potential combined therapy diagnosis HCC. (H epatology 2016;63:1240–1255)